PL342045A1 - 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases - Google Patents

2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases

Info

Publication number
PL342045A1
PL342045A1 PL99342045A PL34204599A PL342045A1 PL 342045 A1 PL342045 A1 PL 342045A1 PL 99342045 A PL99342045 A PL 99342045A PL 34204599 A PL34204599 A PL 34204599A PL 342045 A1 PL342045 A1 PL 342045A1
Authority
PL
Poland
Prior art keywords
benzdiazepin
tetrahydro
inhibitors
hydroxamic acids
matrix metaloproteinases
Prior art date
Application number
PL99342045A
Inventor
Jay Donald Albright
Santos Efren Guillermo Delos
Xuemei Du
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of PL342045A1 publication Critical patent/PL342045A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL99342045A 1998-01-27 1999-01-22 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases PL342045A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1437498A 1998-01-27 1998-01-27
PCT/US1999/001325 WO1999037625A1 (en) 1998-01-27 1999-01-22 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
PL342045A1 true PL342045A1 (en) 2001-05-21

Family

ID=21765097

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99342045A PL342045A1 (en) 1998-01-27 1999-01-22 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases

Country Status (14)

Country Link
EP (1) EP1051407A1 (en)
JP (1) JP2002501056A (en)
KR (1) KR20010034406A (en)
CN (1) CN1293663A (en)
AR (1) AR017230A1 (en)
AU (1) AU2240299A (en)
BR (1) BR9907746A (en)
CA (1) CA2317546A1 (en)
HU (1) HUP0100277A3 (en)
IL (1) IL137162A0 (en)
NO (1) NO20003828L (en)
PL (1) PL342045A1 (en)
WO (1) WO1999037625A1 (en)
ZA (1) ZA99569B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458783B1 (en) 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
AR022423A1 (en) * 1999-01-27 2002-09-04 American Cyanamid Co COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
FR2950057B1 (en) 2009-09-17 2011-08-26 Galderma Res & Dev NOVEL BENZENE CARBOXYLAMIDE COMPOUNDS, PROCESS FOR THEIR SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
FR2950056B1 (en) 2009-09-17 2011-08-26 Galderma Res & Dev NOVEL BENZENE CARBOXYLAMIDE COMPOUNDS, PROCESS FOR THEIR SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
EP3746138B1 (en) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2164914C2 (en) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт CYCLIC AND HETEROCYCLIC N-SUBSTITUTED αIMINO HYDROXAMIC AND CARBOXYLIC ACIDS
CA2238306A1 (en) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation

Also Published As

Publication number Publication date
HUP0100277A2 (en) 2002-02-28
IL137162A0 (en) 2001-07-24
ZA99569B (en) 2000-07-26
WO1999037625A1 (en) 1999-07-29
NO20003828L (en) 2000-09-26
NO20003828D0 (en) 2000-07-26
KR20010034406A (en) 2001-04-25
JP2002501056A (en) 2002-01-15
AU2240299A (en) 1999-08-09
HUP0100277A3 (en) 2002-03-28
CA2317546A1 (en) 1999-07-29
EP1051407A1 (en) 2000-11-15
AR017230A1 (en) 2001-08-22
BR9907746A (en) 2000-10-17
CN1293663A (en) 2001-05-02

Similar Documents

Publication Publication Date Title
PL331854A1 (en) Phosphinamides as inhibitors of metaloprotease matrix
PL342045A1 (en) 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases
ZA981602B (en) Novel hexanoic acid derivatives.
PL348244A1 (en) Substituted indolealkanoic acids
IL135574A0 (en) Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
SI1174431T1 (en) 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
EP1004669A4 (en) Novel differentiation inhibitor
IL138387A0 (en) Enzyme inhibitors
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
PL349025A1 (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
AU2745597A (en) Detergent compositions comprising modified polyamines as dye transfer inhibitors
AU3944497A (en) 1,2-diarylindole as cox-2 inhibitors
GB9806253D0 (en) Amplification of nucleic acids
ZA979756B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
IL129035A0 (en) 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
PL342763A1 (en) Matrix metaloprotease inhibitor
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
ZA974033B (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.
GB9816358D0 (en) Enzyme inhibitors
EP1144305A4 (en) NOVEL sPLA 2 INHIBITORS
HRP970246B1 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
GB9812674D0 (en) Nucleic acids
AU2001235806A1 (en) 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
HK1038013A (en) 2,3,4,5-tetrahydro-1h-[1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors